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ductal carcinoma in 2013. The idea is to develop a short 
course C-ion RT to be finished in one week, which, we 
believe, could replace surgery and more than 5 weeks of 
radiotherapy. The purpose of this report is to evaluate 
preliminary treatment results. 
 
Material and Methods: There are 2 treatment studies. One is 
phase I/II clinical trial and the other is “general treatment 
protocol” (GP). In clinical trial, candidates are patients with 
low-risk stage I breast cancer who are suitable for APBI in 
ASTRO consensus statement. A dose escalation study was 
designed as a phase I clinical trial. Total dose is 48.0 GyE, 
52.8 GyE and 60.0 GyE in 4 fractions within 1 week. In phase 
I, patients planned to undergo surgery for pathological 
evaluation 90 days after C-ion RT and then received 
endocrine therapy. In phase II, patients had C-ion RT at 
recommended dose and then received endocrine therapy. 
Three-field C-ion beams with 290 MeV/n energy are used by 
means of passive broad beam methods using individual 
collimators and a compensation bolus absorber. Irradiation is 
performed using respiratory gating. The other study, GP is for 
the patients desiring to receive C-ion RT but ineligible to 
enroll in the clinical trial due to minor variance or refusal to 
enroll in the clinical trial. The first 2 patients of this GP were 
treated by 52.8 GyE and the others by 60 GyE. All patients 
were suitable for endocrine therapy after RT. 
 
Results: From April 2013 to October 2015, 18 patients were 
treated. There were 3 cases of 48 GyE and 52.8 GyE and 1 
case of 60 GyE of phase I, and 2 cases of 52.8 GyE and 9 cases 
of 60 GyE of GP. Median age was 66 (44 ~ 81). Median tumor 
size was 12 mm (4 ~ 20 mm). Median f/u period was 12 mos. 
No normal tissue adverse events were observed except for 
grade 1 skin reaction of CTC-AE v4 in 9 cases. At the time of 
analysis, 7 patients underwent surgery and 2 of them reached 
pCR. Of the GP patients, 6 reached CR, 4 reached PR and 1 
developed PD on MRI. It took 3 months to 2 years with a 
median of 6 months to reach CR on MRI. So the pathological 
evaluation in phase I trial after 3 months must be too early 
for evaluation. The PD patient with basal subtype tumor was 
successfully salvaged by mastectomy. 
 
Conclusion: C-ion RT for primary tumor of breast needed 
long time to reach CR on MRI. Low grade stage I breast 
cancer has a potential to cure by accelerated partial breast 
irradiation with C-ion RT. 
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Purpose or Objective: to test the maximum tolerated dose 
(MTD) of a concomitant boost to the tumor bed for patients 
at high risk of recurrence treated with whole breast 
radiotherapy (RT). The secondary endpoints are to evaluate 
the acute and late toxicity and the cosmetic result recorded 
by appropriate scales. 
 
Material and Methods: between June and August 2014 we 
selected 9 patients with histologically proven breast cancer 
with pathological stage pT1-2 and at least one of the 
following risk factors for local recurrence: N1 disease, 
lymphovascular invasion, extensive intraductal component, 
close margins, non hormone sensitive disease, grading G3. All 
patients were treated with hypofractionated RT to whole 
breast to a dose of 40.05 Gy in 15 fractions. The dose 
escalation to the tumor bed was delivered through a daily 
concomitant boost technique at 3 levels of dose: 48 Gy (3.2 
Gy/die), 50.25 Gy(3.35 Gy/die) and 52.5 Gy (3.5 Gy/die) for 
the first, second and third level, respectively. We included 3 
patients for each step (3 additional patients if a dose limiting 
toxicity (DLT) Grade ≥ 2 oc curred); dose escalation to a 
higher step was allowed if all patients of the lower one had 
completed the treatment without DLT. MTD was defined as 
the dose level below the dose induced DLT in at least 3 
patients treated at a given dose level. A clinical evaluation of 
the patients was carried out before treatment, 2 times a 
week during RT, at the end of the same, at 3, 6 and 12 
months after the end of RT. In addition to skin toxicity a 
cosmetic evaluation was performed by radiation oncologist, 
an in-training physician and by the patient herself. The latter 
also filled the EORTC QLQ - C30 / BR23 on quality of life at 
each evaluation. 
 
Results: we enrolled a total of 9 patients (3 for each dose 
level) with a median age of 62 years (range 44-83). Patients’ 
characteristics are reported in Table 1. No dose limiting 
toxicity Grade ≥ 2 occurred. The maximum toxicity collected 
during RT was G2 skin toxicity in 7 (77%) patients (2 patients 
with brisk erythema and 5 with moist desquamation). This 
toxicity resolved at the first follow up. At a median follow up 
of 11 months we recorded G2 induration/fibrosis in 3 (33,3%) 
patients, one for each level of dose. There was a worsening 
in the self perception of cosmetic outcome at the end of 
treatment in 6 cases (66%) even if with no statistical 
significance. Moreover, patients at the end of treatment, 
reported a worse (not statistically significant) cosmetic 
outcome compared to that expressed by the in-training 
physician and the radiation oncologist. The evaluation of QoL 
found an improvement of the score at the end of treatment 
compared to initial in 7 of 9 patients (77%), above all in 
elderly patients (≥ 62 years). 
 
 
 
Conclusion 
The 3-week course of postoperative RT with dose escalation 
to the tumor bed to 52,5 Gy has been achieved without dose 
limiting toxicities. Long-term follow-up data are needed to 
assess late toxicity and clinical outcomes. 
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Purpose or Objective: Radiation to the heart during 
radiotherapy (RT) for breast cancer may lead to increased 
risk of ischaemic heart disease years afterwards. A proposed 
method of reducing cardiac dose is with breath-holding 
techniques. Patients undergoing adjuvant breast RT form a 
heterogenous group in terms of demographics and co-
morbidities. We aimed to determine what proportion of 
patients from an unselected group eligible for adjuvant RT 
would be able to comply with a simple breath-holding 
technique pre-treatment, and whether any individual 
characteristics may help predict success or failure. 
 
